Ketamine Is the New Viagra
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
Generic Drugs
-
Read more: Ketamine Is the New Viagra -
Read more: California Enters Insulin Manufacturing: Can We Expect to See a California Effect? California Enters Insulin Manufacturing: Can We Expect to See a California Effect?
Initiatives like CalRx may have far-reaching consequences for public health and access to medicines.
-
Read more: Public Health Product Hops Public Health Product Hops
Are there circumstances for which allowing a product hop resulted in a net benefit to society that exceeded the excess costs associated with the new product?
-
Read more: How Soon Could President Biden Enable Generic Competition to Xtandi? Very Quickly, If There Is the Will. How Soon Could President Biden Enable Generic Competition to Xtandi? Very Quickly, If There Is the Will.
The Biden Administration could take a number of legal measures to ensure the timely entrance of a generic competitor to Xtandi.
-
Read more: Falling Revenue Means Pharmacies in Italy Aren’t Keeping up with Other EU Countries Falling Revenue Means Pharmacies in Italy Aren’t Keeping up with Other EU Countries
Despite Italy being the fifth largest country in the EU for pharmaceutical expenditures, total revenue is dropping.
-
Read more: Book Review: ‘The Truth Pill: The Myth of Drug Regulation in India’ Book Review: ‘The Truth Pill: The Myth of Drug Regulation in India’
The Truth Pill is a monumental work that convincingly shows that drug regulation is but a myth in India.
-
Read more: Reclaiming Global Public Health Reclaiming Global Public Health
The promise of COVID vaccines has been unevenly realized: fault lines have emerged between those able to secure doses and those left behind.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from April 2022.
-
Read more: COVID ‘Compromise’ on International IP Underscores Need for New Approach COVID ‘Compromise’ on International IP Underscores Need for New Approach
For COVID treatments and diagnostics to be broadly available at affordable prices, their IP must be considered a global public good.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from January 2022.
